Japan Should Follow US Efforts to Develop New Antibiotics

PASTEUR Act addresses growing health crisis of global significance

New legislation in the United States Congress is usually a routine occurrence, not a seminal event. But the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, or PASTEUR, Act is different.

It addresses a growing health crisis of global significance that threatens to derail a century of progress against infectious diseases and puts at risk the miracle of longevity that sustains aging societies such as the U.S. and Japan.

The PASTEUR Act, introduced with bipartisan support, will help revive the world’s pipeline of antibiotics — the wonder drugs that protect our societies from infectious diseases and thereby enable healthy, more productive and more fulfilling aging.

Innovative new antibiotics are desperately needed due to a surge in what the medical field calls antimicrobial resistance, or AMR, meaning the evolution of germs that have acquired resistance to the world’s current arsenal of antibiotics.

AMR is a serious health threat, rendering ineffective frequently used treatments for infectious diseases. This problem is already claiming 700,000 lives worldwide every year. Unless new, effective antibiotics are developed that can defeat antibiotic-resistant diseases, the death toll could reach 10 million annually in the coming decades.

This would cripple Organization for Economic Cooperation and Development’s economic growth goals and derail the aims of the World Health Organization’s recently launched Decade of Healthy Aging. While AMR is a crisis for all of society, older adults are most at risk. This fact makes AMR countermeasures a crucial need for Japan, where close to 40% of the population is over 60.

Even as we focus on treatments for non-communicable diseases like cancer and heart disease that have exploded in our aging societies, we cannot let down our guard on treatments for communicable diseases, which is what made the miracle of longevity possible in the first place. It is increasingly the case that infections, paired with aging diseases, are now untreatable and are causing death.

The PASTEUR Act aims to combat this problem by incentivizing the development of new antibiotics that can act as a second line of defense when existing treatments fail. It does this by proposing a new subscription model for antibiotic reimbursement.

Under this model, developers of antibiotics will receive set payments regardless of how many antibiotics they sell. This will incentivize development by allowing developers to recoup development costs without needing to encourage the use of new antibiotics. This is important because once new antibiotics are used, resistance emerges, and what the world needs are treatments that germs cannot resist in case existing treatments become completely unusable in the future.

The introduction of the PASTEUR Act comes on the heels of the Group of Seven health ministers’ recent communique, which devotes an entire section to “the growing pandemic of antimicrobial resistance,” as well as a May expert roundtable on AMR hosted by the Global Coalition on Aging and the Health and Global Policy Institute aimed at addressing the challenges that AMR poses to Japan’s economy and the health of its rapidly aging society.

The new legislation is also aligned with expert recommendations released in March by the AMR Consortium of the Nikkei FT Communicable Diseases Conference Asia Africa Medical Innovation Consortium, calling on Japan to consider a subscription model for antibiotics, or other incentive measures to help address this issue. The legislation also adds to work in this area being completed by the OECD.

This attention is long overdue. For decades, we have taken antibiotics for granted. Between 1950 and today, these drugs became the cornerstone of modern medicine, conquering infections and conditions like bacterial pneumonia, which had been fatal for centuries. During this period, average life expectancy rose by more than a decade in North America, 16 years in Europe, a quarter of a century in Africa, and a staggering 30-plus years in Asia — a surge of progress unparalleled in human history.

Yet, the bacteria that cause many common illnesses persist. Over time, they develop resistance to widely used antibiotics. New threats constantly emerge as germs adapt and evolve to evade even the best treatments. Every therapy, even when used 100% appropriately, generates resistance over time.

Without new antibiotics, we may face a world where there are once again no effective treatments to many fatal infectious diseases, as well as the unraveling of the miracle of longevity in which antibiotics, along with sanitation and childhood immunization, have played a central and powerful role.

This brings us back to the PASTEUR Act, the G-7 and the Japan AMR Roundtable, which was joined by the OECD. COVID-19 has put infectious diseases fully back on the global policy agenda. We have witnessed what medical innovation in the form of several highly effective vaccines developed in record time is capable of achieving.

It is time to turn that same sense of urgency and that same power of innovation to defeating an equally deadly health threat that will also become a fiscal challenge capable of dwarfing what we have just witnessed from COVID-19. AMR is a global threat that cannot be solved by one country alone. We must all commit to progress on this issue.

Passage of the PASTEUR Act in the U.S. would be a great opportunity to demonstrate that commitment. We hope that the new act will become a model for policy action in Japan and the rest of the OECD.

Source: Nikkei Asia

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Best Practices for Engaging a Multigenerational Workforce

Employers are grappling with a myriad of workforce-related issues ranging from productivity to attracting and retaining talent, but many may be overlooking some seismic shifts that are reshaping the future of work: longevity, population aging, and the multigenerational workforce.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

More Than Half of Americans are Unfamiliar with Chronic Kidney Disease, Survey Finds

Chronic kidney disease (CKD) is a major blind spot for many Americans, a new survey suggests. The poll, conducted by the Global Coalition on Aging, asked 1,000 American adults about their understanding and perception of CKD. Though many respondents used the internet for medical information and had a regular doctor and blood work done once or twice a year, 58% of respondents said they were unfamiliar with the illness.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.